Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.66 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789191 | 0.88 | NPC1 (0.61) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL3784499 | 0.87 | NPC1 (0.59) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL3789479 | 0.86 | CASP3 (0.60) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL3792921 | 0.84 | NPC1 (0.57) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL3230293 | 0.84 | NPC1 (0.59) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL3781356 | 0.83 | NPC1 (0.56) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL3793285 | 0.83 | MGLL (0.63) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL3784629 | 0.83 | HDAC1 (0.72) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL9414189 | 0.82 | CTSK (0.55) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL9414187 | 0.82 | CTSK (0.55) | NPC1RAB9AHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975878-B2 | Substituted triazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| EP-2594555-B1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA PHARM CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| WO-2017004522-A1 | HISTONE DEACETYLASE INHIBTORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-10-13 | — | — | US | disclosed |
| EP-1696898-B1 | ZN 2+ -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | UNIV OHIO STATE RES FOUND (US) | 2015-11-18 | — | — | EP | disclosed |
| US-9115090-B2 | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2015-08-25 | — | — | US | disclosed |
| WO-2015076801-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
| EP-1536838-B1 | Hyposensibilisation by hydroxyalkyl starch allergen conjugates | FRESENIUS KABI DE GMBH (DE) | 2007-01-31 | — | — | EP | disclosed |
| EP-1696898-A2 | ZN 24 -CHELATING MOTIF-TETHERED SHORT-CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060121062-A1 | Conjugated hydroxyalkyl starch allergen compounds | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2006-06-08 | — | — | US | disclosed |
| WO-2005055928-A2 | ZN2+ -CHELATING MOTIF-TETHERED SHORT -CHAIN FATTY ACIDS AS A NOVEL CLASS OF HISTONE DEACETYLASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1536838-A1 | CONJUGATED HYDROXYALKYL STARCH ALLERGEN COMPOUNDS | Fresenius Kabi Deutschland GmbH (DE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004030701-A1 | CONJUGATED HYDROXYALKYL STARCH ALLERGEN COMPOUNDS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| EP-0285000-B1 | CHROMOGENE COMPOUNDS, THEIR MANUFACTURE AND USE AS ENZYME SUBSTRATES | Roche Diagnostics GmbH (DE) | 1993-07-28 | — | — | EP | disclosed |
| US-5190862-A | Peptide modified compound | BOEHRINGER MANNHEIM GMBH (DE) | 1993-03-02 | — | — | US | disclosed |
| US-5108890-A | Diagnostic agents for determining peptide bond-cleaving enzymes; measuring light absorbed by liberated colored materials | BOEHRINGER MANNHEIM GMBH (DE) | 1992-04-28 | — | — | US | disclosed |
| EP-0285000-A2 | Chromogene compounds, their manufacture and use as enzyme substrates | Roche Diagnostics GmbH (DE) | 1988-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297798-A1 | SUBSTITUTED TRIAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | NPC1 2824/4885RAB9A 3670/4885HDAC3 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.